Flexion Therapeutics, Inc.
(NASDAQ GM: FLXN)
Rigrodsky Law, P.A. is investigating Flexion Therapeutics, Inc. (“Flexion”) regarding possible breaches of fiduciary duties and other violations of law related to Flexion’s agreement to be acquired by Pacira BioSciences, Inc. Under the terms of the agreement, Flexion’s shareholders will receive $8.50 in cash and one non-tradeable contingent value right worth up to $8.00 per share